Related Experiment Video
Updated: Jul 13, 2026
04:06
A Rat Dry Eye Model with Lacrimal Gland Dysfunction Induced by Scopolamine
Published on: February 9, 2024
Low dose quetiapine induced galactorrhoea: a case report
1Josiah Thomas Memorial Hall, Cornwall Partnership NHS Trust, Camborne, Cornwall, TR14 8LQ, UK. maneesh_psych@yahoo.com
Summary
Quetiapine is known for fewer prolactin issues than other antipsychotics. However, even low doses of quetiapine can cause galactorrhoea and elevated prolactin levels.
Area of Science:
- Pharmacology
- Endocrinology
- Neuroscience
Background:
- Quetiapine is an atypical antipsychotic medication.
- It is generally associated with lower prolactin elevation and galactorrhoea compared to other atypical antipsychotics.
Purpose of the Study:
- To report a case of galactorrhoea and hyperprolactinemia associated with a low dose of quetiapine.
- To highlight that quetiapine, even at lower doses, can induce these side effects.
Main Methods:
- Case presentation of a patient experiencing galactorrhoea and elevated prolactin levels.
- Dosage of quetiapine was 100 mg daily.
Main Results:
- The patient presented with galactorrhoea (milky nipple discharge).
- Laboratory tests revealed elevated prolactin levels.
- These symptoms occurred at a low daily dose of quetiapine (100 mg).
Conclusions:
- Low-dose quetiapine can induce galactorrhoea and hyperprolactinemia.
- This finding contrasts with the general understanding of quetiapine's side effect profile regarding prolactin.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...